TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A preprint study found that transplanted hearts’ molecular age markers shifted toward the biological age of their recipients in mouse experiments and a small human biopsy sample. The findings are preliminary and do not show that older hearts perform better or that the changes improve clinical outcomes.
Transplanted hearts showed molecular age markers that shifted toward the age of their recipients, including signs consistent with rejuvenation when older hearts were placed in younger mice, according to a non-peer-reviewed preprint posted on bioRxiv. Researchers also reported a similar age-related pattern in archived biopsies from 11 human transplant recipients, but the findings do not establish that the shifts improve heart function or patient outcomes.
Teams led by researchers at Brigham and Women’s Hospital and Harvard Medical School studied how an age-mismatched recipient’s body might affect a transplanted heart. In mouse experiments, they used heterotopic transplants: the recipient kept its own heart while a donor heart was connected to blood vessels in the neck. The researchers assessed the animals four to six months after transplantation, using DNA methylation markers, transcriptomic sequencing and other measures related to biological aging.
The molecular results varied with the direction of the age mismatch. Age-prediction measures indicated that older donor hearts in younger recipients shifted toward a younger profile, while younger donor hearts in older recipients showed changes consistent with aging. The researchers also found related patterns in gene activity, including changes in inflammatory and interferon processes and in mitochondrial functions such as oxidative phosphorylation and respiratory electron transport.
The team then examined archived heart biopsies from 11 human recipients, whose donors’ ages ranged from 24 years younger to 50 years older than the recipients. The estimated biological age of the transplanted hearts was associated with recipient age, resembling the pattern seen in mice. A separate analysis of detailed outcomes in hundreds of recipients one year after transplant found that recipient age was associated with several functional measures, most consistently exercise capacity. That analysis offers clinical context, but it does not by itself show that molecular age shifts caused differences in those outcomes.
Could Age Shifts Expand Donor Options?
Heart transplantation is limited by the number of suitable donor organs. The report notes that donor hearts are often selected with a preference for younger donors, although there is no official upper age limit and practices differ among transplant programs. If further research confirms that a recipient’s body can alter some biological features of a donor heart, that could inform how scientists assess organs from older donors.
That possibility is not yet a change in clinical practice. The study measured molecular features associated with age; it did not establish that an older heart became functionally younger, lasted longer, or was safer to transplant. The findings also do not show that age alone should determine whether a particular heart is suitable. Decisions about donor organs depend on clinical assessment, and any change to donor selection would require stronger evidence.
As an affiliate, we earn on qualifying purchases.
Age-Mismatched Heart Transplants
The researchers describe these procedures as heterochronic transplantation, meaning an organ from a donor of one age is placed in a recipient of a different age. The question is whether the organ’s surrounding environment, including blood-borne and systemic factors, can alter its age-related biology. Earlier research cited in the report has examined whether exposure to a younger organism’s systemic environment affects aging features in older tissues; this study tests the question in transplanted hearts.
The demand for transplantation has grown as populations age, while the supply of donor organs remains limited. The report cites a 127% increase in U.S. heart-transplant recipients aged 65 or older between 2010 and 2021. It also says donors younger than 45 are generally recommended and relatively few programs accept hearts from donors older than 50. These figures describe the background to the research, not a change in donor eligibility rules.
“The biological age of heterochronic heart implants is strongly affected by the recipient’s age.”
— The study authors, as summarized in the News-Medical report
longevity and anti-aging supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Molecular Results Cannot Show
The work is available as a preprint and has not been peer-reviewed. The human biopsy analysis included only 11 recipients, and the report does not provide enough detail to determine how representative those samples are or whether the observed shifts persisted over time. It also does not establish the specific biological processes that may drive the changes.
Most importantly, a younger-looking molecular profile is not the same as better clinical performance. The findings do not prove that older donor hearts are rejuvenated in a way that improves survival, reduces complications or extends graft function. The report gives no basis for changing medical practice, and it remains unclear whether the molecular shifts are a cause of functional differences, a consequence of the transplant environment, or simply associated with recipient age.
As an affiliate, we earn on qualifying purchases.
Peer Review and Clinical Follow-Up
The next steps are independent review and further research to test whether the findings hold in larger and more diverse groups of transplant recipients. Longer follow-up could help determine whether age-associated molecular changes persist and whether they track with meaningful measures such as graft function, exercise capacity, complications or survival.
Until those questions are addressed, the result is best treated as an early research finding, not evidence for accepting organs that would otherwise be unsuitable. The supplied report does not identify a publication schedule, planned trial or specific next milestone from the research team.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find about older donor hearts?
In mouse experiments, older transplanted hearts in younger recipients developed DNA methylation and gene-activity patterns consistent with a younger biological profile. A similar association between recipient age and estimated heart age was reported in biopsies from 11 human recipients.
Does this prove older hearts work better in younger recipients?
No. The study reports molecular age markers and does not prove that the changes improve heart function, survival or other clinical outcomes.
Was the study peer-reviewed?
No. It was posted as a bioRxiv preprint, which means it had not completed peer review at the time of the report.
Could the findings change which donor hearts are accepted?
Not on their own. The findings are preliminary and do not establish that older donor hearts are suitable or safe in cases where they otherwise would not be accepted. The report does not describe a change to transplant eligibility guidance.
Did the transplanted hearts change the recipients’ other organs?
The report says biological-age measures in the recipients’ native heart, liver and blood mostly remained unchanged after transplantation. The observed age-related shifts were more apparent in the transplanted heart.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
